FUSION PHARMACEUTICALS INC's ticker is FUSN and the CUSIP is 36118A100. A total of 38 filers reported holding FUSION PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,543,342 | -44.3% | 3,670,516 | 0.0% | 3.52% | -34.0% |
| Q2 2023 | $17,141,310 | +23.9% | 3,670,516 | 0.0% | 5.32% | +18.2% |
| Q1 2023 | $13,837,845 | +119583.8% | 3,670,516 | 0.0% | 4.50% | +33.8% |
| Q4 2022 | $11,562 | -99.9% | 3,670,516 | 0.0% | 3.36% | +3.5% |
| Q3 2022 | $11,048,000 | +20.9% | 3,670,516 | 0.0% | 3.25% | +39.2% |
| Q2 2022 | $9,140,000 | -68.0% | 3,670,516 | 0.0% | 2.34% | -56.7% |
| Q1 2022 | $28,520,000 | +86.3% | 3,670,516 | 0.0% | 5.39% | +209.5% |
| Q4 2021 | $15,306,000 | -47.3% | 3,670,516 | 0.0% | 1.74% | -31.7% |
| Q3 2021 | $29,070,000 | – | 3,670,516 | – | 2.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ADAMS STREET PARTNERS LLC | 2,973,744 | $24,028,000 | 4.99% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,598,377 | $12,613,000 | 4.97% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,670,516 | $29,658,000 | 3.03% |
| Sio Capital Management, LLC | 266,107 | $2,150,000 | 0.53% |
| Orbimed Advisors | 3,224,770 | $26,056,000 | 0.26% |
| Perceptive Advisors | 3,550,334 | $28,686,000 | 0.19% |
| AlphaCentric Advisors LLC | 71,500 | $578,000 | 0.16% |
| Rock Springs Capital Management LP | 948,327 | $7,662,000 | 0.15% |
| TPG Group Holdings (SBS) Advisors, Inc. | 2,551,794 | $20,618,000 | 0.15% |
| Artal Group S.A. | 750,000 | $6,060,000 | 0.12% |